# **Endocrine Disruptors -**

worldwide registration

# Recent global regulatory developments and data requirements for endocrine disruptor testing and assessment

# Martina Duft, Agnes Schimera, Anja Rämisch

"An endocrine disruptor is an exogenous substance or mixture that alters function(s) of the endocrine system and consequently causes adverse health effects in an intact organism, or its progeny, or (sub) populations" (WHO, ICPS, 2002)

knoell

#### Introduction

Despite decades of scientific research as well as extensive discussions and work within regulatory panels, an intended consensus on the assessment of substances with an endocrine disrupting potential, so-called **endocrine disruptors**, has not yet been reached.

Various diverging proposals for an assessment of industrial chemicals, plant protections products or biocidal products to consider potential endocrine effects are available. This poster aims to give a global overview on present regulatory proposals, recent regulatory developments and data requirements for the **assessment** of endocrine disrupting chemicals.




#### European Commission (EC):

- Development of Community Strategy for EDCs: short-/medium-/long-term activities
- Priority list of substances for further evaluation
- 2014/15: Roadmap and Public Consultation to define criteria for identifying EDCs (plant protection and biocidal products regulation)
- 2016: Criteria to be announced before summer

Biocidal Products Regulation (528/2012), Plant Protection Products Regulation (1107/2009):

- Non-approval of substances considered
  to have endocrine disrupting properties; interim criteria
- Exceptions: negligible exposure/risk, necessity of substance to combat serious pests REACh (1907/2006):
- Eligible as substances of very high concern, SVHC (equivalent level of concern (Art. 57f) as for PBT, CMR substances) authorisation required, socio-economic analysis
  Cosmetics Regulation (1223/2009):
- Currently under review, EDCs not restricted

#### European Food Safety Authority (EFSA):



USA

## US EPA:

 Endocrine Disruptor Screening Program (EDSP): two-tiered testing strategy (estrogen, androgen and thyroid hormonal systems, and wildlife)


Tier 1: identification and classification of potential EDCs by in-vitro and in-vivo assays; Series 890 - EDSP Test Guidelines

Tier 2: concentration-response relationships in animal models; TGs partly under development

 initial list of chemicals to be screened in 2009; second list in 2010, final in 2014

Future objectives according to **Comprehensive Management Plan** for 2014-2019:

- List 1 chemicals: Data review of all Tier 1 assays results together with scientifically relevant data → decision on Tier 2 testing and test orders by US EPA (results from Tier 2 data reviews will directly support risk assessments for registration review and new registration actions). 2015: Tier 1 screening results for 52 chemicals published.
- Further priorization of List 2 chemicals and decisions on exemption of some chemicals from Tier 1 testing.
- Promotion of computational toxicology and exposure methods, e.g. ToxCast<sup>TM</sup>, for



Aiming to evaluate probable endocrine disrupting properties of pesticides

### Thailand

No specific legislation or regulatory program concerning EDCs, however the *Hazardous Substance Act B.E. 2535* (1992) may be used for dealing with EDCs. Chemicals are classified into type 1, 2, 3 or 4 based on toxicological data, dangerous

 Development of test methods, hazard and risk assessment, risk management, information sharing and risk communication

#### Several projects were launched:

 SPEED '98: literature research on endocrine disrupting effects on wildlife, determination of chemicals to be tested (VTG assay, *Medaka* fish assays)

properties, international obligations and necessity. For type 4 compounds, production, import, export and possession is prohibited. Hazardous substances are compiled in the Notification List B.E. 2556 (2013, 2015).

#### South Korea

Since 2001: Collaboration Korea-Japan. 1999: Mid-long term research plan for suspected endocrine disruptors. 2007-2011: 5-year research plan, review of results, safety management of EDCs. 2013: K-REACh: authorisation, restriction for EDCs.

#### Conclusion

As scientific criteria for the evaluation of endocrine disrupting properties of a substance are still not available yet, assessment is mostly conducted on a case-by-case basis at the moment. For companies intending or supporting global registrations for their substances, this results in substantial uncertainty regarding data requirements or testing and assessment strategies.

- → "Weight of evidence" evaluation and expert assessments tailored for respective regulatory programs are required for evaluation of endocrine disrupting properties of the substances.
- $\rightarrow$  Envisaged or requested studies should be carefully set up to meet global requirements and to avoid redundant testing.
- $\rightarrow$  Results obtained by studies prepared for one regulatory program will need to be dealt with in any other regulatory program.

- ExTEND 2005: various chemicals tested for endocrine effects on *Medaka* fish
- ExTEND 2010: further actions on EDCs, and establishment of assessment methods and environmental risk assessment.
- Collaboration with US regarding test guideline development (EDSP)

#### risk-based assessment

#### References

www.oecd.org/env/ehs/testing/oecdworkrelatedtoendocrinedisrupters www.env.go.jp/ed http://www.fda.gov/ScienceResearch/BioinformaticsTools www.jetro.go.jp/thailand www.epa.gov/endo/

#### Acknowledgements

Many thanks to our colleagues from Dr. Knoell Consult Thai Co. Ltd. and Dr. Knoell Consult Shanghai Co. Ltd. for their support.

Dr. Knoell Consult GmbH | Dynamostr. 19 | D-68165 Mannheim | Germany | Tel. +49 621 718858 - 282 | Fax. -100 | mduft@knoell.com | www.knoell.com